Sorafenib tablets 200mg/tablet, 120 tablets/box

Medication Safety Tips

Use this product according to its instructions, medical advice, and your health needs. Shipping is arranged after payment once the order meets dispatch requirements.

Contraindications

Warnings and Precautions
• Cardiovascular events: Consider temporarily or permanently discontinuing LuciSora.
• Bleeding: Disable LuciSora if necessary.
• Blood Pressure: Blood pressure is monitored weekly for the first 6 weeks and then regularly thereafter.
• Skin toxicity: discontinuation and/or dose reduction. Severe or persistent reactions, or suspected Stevens-Johnson syndrome and toxic epidermal necrolysis, should be discontinued.
• Gastrointestinal perforation: LuciSora was discontinued.
• Prolonged QT interval: Monitor electrocardiogram and electrolytes in patients at increased risk of ventricular arrhythmias.
• Drug-induced liver injury: Monitor liver function regularly; discontinue if unexplained transaminase increase occurs.
• Embryo-fetal toxicity: LuciSora may cause harm to the fetus. Inform the patient of the potential risks to the fetus and use effective contraception.
• Impaired TSH Suppression in DTC: Monthly monitoring of TSH and adjustment of thyroid replacement therapy in patients with thyroid cancer.

Medication risks

Adverse Reactions
The most common adverse effects (≥ 20%) of LuciSora are diarrhea, fatigue, infection, hair loss, hand-foot skin reaction, rash, weight loss, decreased appetite, nausea, gastrointestinal and abdominal pain, Blood Pressure, and bleeding.